Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex

Vertex 2024: see how HaZ Dulull blurs the line between film and video games in Unreal Engine

The producer, director and HaZimation co-founder will discuss his transmedia approach to producing IP in movies and games.

Creative Bloq

Find your tribe at Vertex

Join us to connect and learn at the ultimate festival of digital art, animation and VFX.

Creative Bloq

Vertex 2024 speaker: learn insights from Dolph Souza's 3D workflow

The animator and director will share some of his process at this year's event.

Creative Bloq

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex 2024: learn how to build worlds in concept art with Anna Hollinrake

The award-winning art director will share tips on how to confront a blank sheet of paper.

Creative Bloq

Vertex 2024: learn how to use Unreal Engine to create IPs with David Levy

The international art director will guide attendees through the development of his new film, from inception to render.

Creative Bloq

Vertex 2024 speaker: gain insights from Alina Fedaseyenka's art for Synapse

The freelance concept artist will share her process at our live art event.

Creative Bloq

Vertex 2024 speaker: learn from artist Nana Dhebuadze's keyframe pipeline

The freelance concept artist will share her process at our live art event.

Creative Bloq

Read news from The Economist, FT, and more,
with one subscription

Vertex 2024 speaker: gain tips on meeting clients' demands from Andy Hammond

Maverick Media's creative director is one of the speakers at this year's event.

Creative Bloq

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

StockNews.com

Vertex 2024 speaker: learn from the fresh voice of art director Ibby Karim

Ibby will share experiences of working with big-name IPs at Vertex 2024.

Creative Bloq

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points

S&P 500 stocks Lennar, Vertex Pharmaceuticals and Royal Caribbean lead this list of five stocks trading around buy points.

Investors Business Daily

Vertex 2024 speaker: Moog Gravett on cinematics and technical art

The award-winning creative director is a guest at Vertex 2024.

Creative Bloq

Here's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Investors Business Daily

This Could Be the Next Blockbuster Drug Stock to Buy

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Creative Bloq

Vertex 2024 speaker: learn new art skills from creature designer Brynn Metheney

The Ghostbusters concept artist will be at Vertex 2024.

StockNews.com

Why Investors Are Flocking to These 2 Medical Stocks

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

Investors Business Daily

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

The stock market rally hit fresh highs, with the S&P 500 hit 5,000. Arm and Palantir skyrocketed, with several other AI plays running higher.

Investors Business Daily

Vertex Is Trying To Replace Its Biggest Drug — Does It Stand A Chance?

Vertex could bolster its cystic fibrosis franchise with a next-generation drug, analysts said Tuesday. But VRTX stock dipped.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Vertex Rebounds — But Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst

Vertex's alternative to opioids is "not a game-changer," an analyst said Tuesday. But VRTX stock rebounded on the company's test results.

Investors Business Daily

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Investors Business Daily

Vertex, IBD Stock Of The Day, Called 'Underappreciated Winner' For 2024

Vertex is the IBD Stock Of The Day as the maker of corporate tax compliance software expands its footprint with an acquisition.

The Hindu

What incentives do scientists have to study rare diseases? | Explained

Explore the cutting-edge research of three Breakthrough Prize laureates in Life Sciences, and the systemic issues that influence access to treatments for three diseases desperately looking for cures: Parkinson’s disease, cystic fibrosis, and cancer.

The Independent UK

Promising new gene therapies for sickle cell are out of reach in countries where they're needed most

New gene therapies promise a cure for sickle cell disease but experts say they are out of reach in places that need them the most

Investors Business Daily

Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment

Vertex solidified its potential for an alternative to opioids in pain treatment, an analyst said Wednesday. VRTX stock broke out.

Investors Business Daily

Vertex Stock Breaks Out On Phase 2 Results For Opioid Alternative

Vertex stock rallied 13% Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.